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The standard treatment for de novo acute myeloid leukemia (AML) has been established. 
Although patients with AML achieve complete remission at high rates, the long-term 
prognosis for such patients remains unsatisfactory. It is therefore necessary to perform 
hematopoietic stem cell transplantation (HSCT) to improve their prognoses, however, a 
high rate of transplant-related mortality continues to be a problem associated with 
allogeneic HSCT. We therefore need to carefully determine the indications to safely 
perform HSCT based on historical data. 
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2. 我が国における移植ガイドラインと初診時 AMLの予後予測 






るかについて明確な記載がなく、Medical Research Council（MRC）(3) と South Western 
Oncology Group（SWOG）(4)による染色体核型による予後分類と、National Comprehensive 
Cancer Network（NCCN）のガイドラインを例示している(5) (Accessed 2016 May 5.)。SWOG
とMRCのガイドラインは、どちらも染色体核型により予後良好群、中間群、不良群の3群に分類
している。しかし遺伝子異常が考慮されておらず、また提唱されたのは2000年前後であることか

























植は CO：移植を考慮しても良い、としている。しかし近年、HLA-A, B, C, DRB1がアリルレベル
で適合している非血縁者間移植の成績は HLA適合同胞間移植の成績と同等と報告されている
(10)。また、骨髄バンクでのドナーコーディネート期間中央値および最頻値が迅速コース導入前














 5 / 10 
 
の群に含まれる。また、FLT3-ITD変異または TP53変異を持つ正常核型症例は予後不良であ
































が国の移植データベースの解析でも示されている(21). （Accessed 2016 May 5.）。そのため、
予後分類標準リスク群では、第一寛解期では移植を行わず、再発後の第二寛解で同種移植を
行う、という戦略も考えられる。しかし、第一寛解で移植を行わなかった例が、再発後に第二寛











酸（all trans retinoic acid; ATRA）と化学療法の併用療法や、亜ヒ酸（arsenic trioxide; ATO）に

















































Table 1. The indications for hematopoietic stem cell transplantation in AML patients (except 
APL). 
Table 2. The risk status according to the NCCN guidelines version 1, 2016. 




1. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. 
A randomized comparison of 4 courses of standard-dose multiagent 
chemotherapy versus 3 courses of high-dose cytarabine alone in postremission 
therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 
2011;117(8):2366-72. 
2. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. 
Randomized study of induction therapy comparing standard-dose idarubicin 
with high-dose daunorubicin in adult patients with previously untreated acute 
 8 / 10 
 
myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117(8):2358-65. 
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, 
et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 
1,612 patients entered into the MRC AML 10 trial. The Medical Research 
Council Adult and Children's Leukaemia Working Parties. Blood. 
1998;92(7):2322-33. 
4. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, 
Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and 
postremission therapy in adult acute myeloid leukemia: a Southwest Oncology 
Group/Eastern Cooperative Oncology Group Study. Blood. 
2000;96(13):4075-83. 
5. Network NCC. Acute Myeloid Leukemia, Version 1, 2016. NCCN 
Clinical Practice Guidelines in Oncology (NCCN Guidelines) 2016 [Available 
from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. 
6. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett 
AK, et al. Diagnosis and management of acute myeloid leukemia in adults: 
recommendations from an international expert panel, on behalf of the European 
LeukemiaNet. Blood. 2010;115(3):453-74. 
7. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, 
et al. The value of allogeneic bone marrow transplant in patients with acute 
myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 
trial. Br J Haematol. 2002;118(2):385-400. 
8. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et 
al. Allogeneic stem cell transplantation for acute myeloid leukemia in first 
complete remission: systematic review and meta-analysis of prospective 
clinical trials. JAMA. 2009;301(22):2349-61. 
9. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic 
hematopoietic stem cell transplantation depends on cytogenetic risk for acute 
myeloid leukemia in first disease remission: a metaanalysis. Cancer. 
2005;103(8):1652-8. 
10. Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, et al. 
Related transplantation with HLA-1 Ag mismatch in the GVH direction and 
HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective 
study. Blood. 2012;119(10):2409-16. 
11. 日本骨髄バンク. コーディネート期間（2015年度実績）  [Available 
from: http://www.jmdp.or.jp/coordinate/kanri/co-kikan-2015do.pdf. 
 9 / 10 
 
12. 日本骨髄バンク. コーディネート期間（2003年 1月～12月実績）  
[Available from: http://www.jmdp.or.jp/coordinate/kanri/co-kikan-20031-12.pdf. 
13. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, 
et al. Disease-specific analyses of unrelated cord blood transplantation 
compared with unrelated bone marrow transplantation in adult patients with 
acute leukemia. Blood. 2009;113(8):1631-8. 
14. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. 
Allogeneic compared with autologous stem cell transplantation in the treatment 
of patients younger than 46 years with acute myeloid leukemia (AML) in first 
complete remission (CR1): an intention-to-treat analysis of the 
EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232-40. 
15. Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, 
Pabst T, et al. Comparative analysis of the value of allogeneic hematopoietic 
stem-cell transplantation in acute myeloid leukemia with monosomal karyotype 
versus other cytogenetic risk categories. J Clin Oncol. 2012;30(17):2140-6. 
16. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef 
GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid 
leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-78. 
17. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. 
Factors predicting outcome after unrelated donor stem cell transplantation in 
primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808-13. 
18. Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill 
T, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail 
primary induction therapy. Biol Blood Marrow Transplant. 2015;21(3):559-64. 
19. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. 
Curability of patients with acute myeloid leukemia who did not undergo 
transplantation in first remission. J Clin Oncol. 2013;31(10):1293-301. 
20. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori 
H, et al. Prognostic factors and outcomes of adult patients with acute myeloid 
leukemia after first relapse. Haematologica. 2010;95(11):1857-64. 
21. 日本造血細胞移植データセンター. 日本における造血細胞移植。平成
26年度全国調査報告書 Ⅲ. 移植アウトカムの成績、AML症例での生存曲線 
2016 [Available from: http://www.jdchct.or.jp/data/report/2014/3-3-2.pdf. 
22. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, 
Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of 
patients with relapsed acute promyelocytic leukemia induced with arsenic 
 10 / 10 
 
trioxide and consolidated with either an autologous stem cell transplant or an 
arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 
2009;15(11):1479-84. 
23. de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, et al. 
Autologous and allogeneic stem-cell transplantation as salvage treatment of 
acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a 
retrospective analysis of the European acute promyelocytic leukemia group. J 
Clin Oncol. 2005;23(1):120-6. 
24. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K, et 
al. Comparison of reduced-intensity hematopoietic cell transplantation with 
chemotherapy in patients age 60-70 years with acute myelogenous leukemia in 
first remission. Biol Blood Marrow Transplant. 2011;17(12):1796-803. 
25. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, 
Chauncey TR, et al. Long-term outcomes among older patients following 
nonmyeloablative conditioning and allogeneic hematopoietic cell 
transplantation for advanced hematologic malignancies. JAMA. 
2011;306(17):1874-83. 
26. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 
2012;47(6):749-56. 
27. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, 
et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a 
new tool for risk assessment before allogeneic HCT. Blood. 
2005;106(8):2912-9. 
28. Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, et al. 
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) 
predict transplantation outcomes? A prospective multicenter validation study of 
the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant. 
2014;20(10):1553-9. 
 
Table 1. Indication for hematopoietic stem cell transplantation 
in AML patients (except APL) 
JSHCT guideline AML(adult), ver.2, modified. 
Table 2. Risk status by NCCN guidelines version 1, 2016. 
JSHCT guideline AML(adult), ver.2, modified. 
Table 3. Indication for hematopoietic stem cell transplantation 
in APL patients 
